Business Wire08.19.21
Cala Health Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, has expanded its executive team with medical technology industry veterans Steve Higa as vice president, Manufacturing & Quality, and Greg Schulte as vice president, Hardware.
“The additions of these seasoned professionals, Steve and Greg, to our team supports the current on-market Cala Trio device and expands our capabilities for our pipeline of future products in development to treat conditions using electricity as medicine,” said Renee Ryan, CEO.
Higa has held numerous manufacturing, operational, and engineering roles in Silicon Valley. Prior to joining Cala Health, he worked as vice president of Manufacturing for miraDry and held a vice president of Operations role for Zoll Circulation. He earned an M.S. degree in electrical engineering from Santa Clara University.
Schulte has 20 years of experience in product strategy, design, and engineering for companies and clients of all sizes focused in medical, utility, and consumer electronics. A mechanical engineer by training, Schulte cofounded Guide Medical Ventures in 2011, managing strategic vision and technology for a portfolio of six startups in the medical device space. Prior to joining Cala Health, Schulte led engineering at Mindtribe, a boutique hardware development consultancy acquired by Accenture. Schulte started his career at Medtronic plc as a mechanical design engineer in neuromodulation and honed his engineering leadership at Intelect Medical (acquired by Boston Scientific Corp.), Enpath Medical, and EnteroMedics.
Cala Health Inc., headquartered in the San Francisco Bay area, developed wearable neuromodulation therapies that utilize electricity as medicine, merging innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. Its vertically integrated commercial model is transforming the delivery of prescription therapies. Cala Health’s lead product, Cala Trio, is the only non-invasive, wrist-worn prescription therapy currently available for essential tremor. Cala Health has new therapies under development in neurology, cardiology, and mental health and is backed by leading investors in both healthcare and technology.
“The additions of these seasoned professionals, Steve and Greg, to our team supports the current on-market Cala Trio device and expands our capabilities for our pipeline of future products in development to treat conditions using electricity as medicine,” said Renee Ryan, CEO.
Higa has held numerous manufacturing, operational, and engineering roles in Silicon Valley. Prior to joining Cala Health, he worked as vice president of Manufacturing for miraDry and held a vice president of Operations role for Zoll Circulation. He earned an M.S. degree in electrical engineering from Santa Clara University.
Schulte has 20 years of experience in product strategy, design, and engineering for companies and clients of all sizes focused in medical, utility, and consumer electronics. A mechanical engineer by training, Schulte cofounded Guide Medical Ventures in 2011, managing strategic vision and technology for a portfolio of six startups in the medical device space. Prior to joining Cala Health, Schulte led engineering at Mindtribe, a boutique hardware development consultancy acquired by Accenture. Schulte started his career at Medtronic plc as a mechanical design engineer in neuromodulation and honed his engineering leadership at Intelect Medical (acquired by Boston Scientific Corp.), Enpath Medical, and EnteroMedics.
Cala Health Inc., headquartered in the San Francisco Bay area, developed wearable neuromodulation therapies that utilize electricity as medicine, merging innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. Its vertically integrated commercial model is transforming the delivery of prescription therapies. Cala Health’s lead product, Cala Trio, is the only non-invasive, wrist-worn prescription therapy currently available for essential tremor. Cala Health has new therapies under development in neurology, cardiology, and mental health and is backed by leading investors in both healthcare and technology.
